Adenosine A3 receptor-mediated cardioprotection against doxorubicin-induced mitochondrial damage

Biochemical Pharmacology

Volumn 79, Issue 2, 2010, Pages 180-187

  Emanuelov, Avishag K ^a   Shainberg, Asher ^a   Chepurko, Yelena ^b   Kaplan, Doron ^c   Sagie, Alex ^d   Porat, Eyal ^d   Arad, Michael ^e   Hochhauser, Edith ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e SHEBA MEDICAL CENTER   (Israel)

Author keywords

A3 adenosine receptors; Ca2+ homeostasis; Cl IB MECA; Doxorubicin

Indexed keywords

2 CHLORO 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLURONAMIDE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE TRIPHOSPHATASE (CALCIUM); CAFFEINE; CALCIUM; DOXORUBICIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOSOL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; HEART CELL CULTURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE WALL; HEART MUSCLE CELL; HEART PROTECTION; IN VIVO STUDY; MALE; MITOCHONDRION; NON INVASIVE MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOPLASMIC RETICULUM; ANIMAL; CELL CULTURE; DRUG EFFECT; NEWBORN; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; DOXORUBICIN; MALE; MITOCHONDRIA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A3;

EID: 71749115994     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.08.010     Document Type: Article

References (35)

1. Lum B.L., Gosland M.P., Kaubisch S., and Sikic B.I. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy 13 (1993) 88-109 [review]
2. Takemura G., and Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49 (2007) 330-352
3. Outomuro D., Grana D.R., Azzato F., and Milei J. Adriamycin-induced myocardial toxicity: new solutions for an old problem?. Int J Cardiol 117 (2007) 6-15
4. Robert J. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. Cardiovasc Toxicol 7 (2007) 135-139
5. Tokarska-Schlattner M., Zaugg M., Zuppinger C., Wallimann T., and Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41 (2006) 389-405
6. 3 adenosine receptor protects against doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 33 (2001) 1249-1261
7. 3 adenosine receptor. J Mol Cell Cardiol 34 (2002) 493-507
8. Yitzhaki S., Shainberg A., Cheporko Y., Vidne B.A., Sagie A., Jacobson K.A., and Hochhauser E. Uridine-5'-triphosphate (UTP) reduces infarct size and improves rat heart function after myocardial infarct. Biochem Pharmacol 72 (2006) 949-955
9. 3 adenosine receptor agonist. Exp Cell Res 243 (1998) 383-397
10. 3 receptor activation during hypoxia in isolated rat cardiac myocytes. Mol Cell Biochem 217 (2001) 143-152
11. i relaxation in cardiomyocyte contraction following various drug treatments. Cell Calcium 31 (2002) 279-287
12. Jo H., Noma A., and Matsuoka S. Calcium-mediated coupling between mitochondrial substrate dehydrogenation and cardiac workload in single guinea-pig ventricular myocytes. J Mol Cell Cardiol 40 (2006) 394-404
13. Cole M.P., Chaiswing L., Oberley T.D., Edelmann S.E., Piascik M.T., Lin S.M., et al. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. Cardiovasc Res 69 (2006) 186-197
14. Sterba M., Popelová O., Simunek T., Mazurová Y., Potácová A., Adamcová M., et al. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. J Pharmacol Exp Ther 319 (2006) 1336-1347
15. Yeh E.T., Tong A.T., Lenihan D.J., Yusuf S.W., Swafford J., Champion C., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109 (2004) 3122-3131
16. Bruynzeel A.M., Abou El Hassan M.A., Schalkwijk C., Berkhof J., Bast A., et al. Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice. Br J Cancer 96 (2007) 937-943
17. Roffe L., Schmidt K., and Ernst E. Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review. J Clin Oncol 22 (2004) 4418-4424
18. Fisher P.W., Salloum F., Das A., Hyder H., and Kukreja R.C. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111 (2005) 1601-1610
19. Singal P.K., and Iliskovic N. Doxorubicin-cardiomyopathy. N Engl J Med 339 (1998) 900-905
20. Bristow M.R., Mason J.W., Billingham M.E., and Daniels J.R. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 102 (1981) 709-718
21. Chalcroft S.C.W., Gavin J.B., and Herdson P.B. Fine structural changes in rat myocardium induced by dunorubicin. Pathology 5 (1973) 99-105
22. Mettler F.P., Young D.M., and Ward J.M. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 37 (1977) 2705-2713
23. Wakasugi S., Fischman A.J., Babich J.W., et al. Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy. J Nucl Med 34 (1993) 1529-1535
24. Pye M.P., Black M., and Cobbe S.M. Comparison of in vivo and in vitro haemodynamic function in experimental heart failure: use of echocardiography. Cardiovasc Res 31 (1996) 873-881
25. Schwarz E.R., Pollick C., Dow J., Patterson M., Birnbaum Y., and Kloner R.A. A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography. Cardiovasc Res 39 (1998) 216-223
26. Xiang P., Deng H.Y., Li K., Huang G.Y., Chen Y., Tu L., et al. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model. Cancer Chemother Pharmacol 63 (2009) 343-349
27. Serrano J., Palmeira C.M., Kuehl D.W., and Wallace K.B. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim Biophys Acta 1411 (1999) 201-205
28. Olson R.D., and Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4 (1990) 3076-3086
29. 2+ handling. Jpn Circ J 64 (2000) 65-71
30. Halili-Rutman I., Hershko C., Link G., Rutman A.J., and Shainberg A. Inhibition of calcium accumulation by the sarcoplasmic reticulum: a putative mechanism for the cardiotoxicity of adriamycin. Biochem Pharmacol 54 (1997) 211-214
31. Szabadkai G., and Rizzuto R. Participation of endoplasmic reticulum and mitochondrial calcium handling in apoptosis: more than just neighborhood?. FEBS Lett 567 (2004) 111-115
32. Andersson K.B., Birkeland J.A., Finsen A.V., Louch W.E., Sjaastad I., Wang Y., et al. Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene. J Mol Cell Cardiol 47 (2009) 180-187
33. Trafford A.W., Lederer W.J., and Sobie E.A. Keeping the beat: life without SERCA-is it possible?. J Mol Cell Cardiol 47 (2009) 171-173
34. Fabritz L., Kirchhof P., Fortmüller L., Auchampach J.A., Baba H.A., Breithardt G., et al. Gene dose-dependent atrial arrhythmias, heart block, and Brady-cardiomyopathy in mice overexpressing A(3) adenosine receptors. Cardiovasc Res 62 (2004) 447-449
35. Bar-Yehuda S., Stemmer S.M., Madi L., Castel D., Ochaion A., Cohen S., et al. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol 33 (2008) 287-295